Results 21 to 30 of about 21,372 (208)

Venetoclax with Azacitidine or Low Dose Cytarabine As an Alternative to Intensive Chemotherapy in Fit Adults during the COVID19 Pandemic: Real World Data from the UK National Health Service

, 2021
BackgroundBased on early evidence of a high rate of coronavirus mortality in patients with acute myeloid leukaemia (AML) undergoing intensive chemotherapy (IC), the national health service (NHS) in the United Kingdom temporarily made venetoclax available
Crolla, Francesca, Taussig, David, Dalley, Chris, Mobashwera, Behnaz, Bashford, Alex, Khan, Anjum, Coats, Thomas, Othman, Jad, Marshall, Scott R., Anderson, Laura, Radzova, Dominika, Amer, Mariam, Khwaja, Asim, Smith, Matthew, Orthi, Shahzad, Latif, Annie, Rye, Adam, Belsham, Edward, Hodgson, Katherine, Crawley, Charles, Ochaya, Odong, Saunders, Jamie, Laurie, John, Katsomitrou, Vana, Austin, Michael J, Freeman, Sylvie D, Cross, Joe W, Kalkur, Pallavi, Jain, Manish, Dhawan, Saniya, Pillai, Srinivas, Manson, Cara, Amofa, Ruebina, Mannari, Deepak, Taylor, Tom, Elliott, Johnathon, Murthy, Vidhya, Craddock, Charles, Krishnamurthy, Pramila, Zhao, Rui, Dang, Raymond, Boot, Jesca, Loke, Justin, Galli, Sofia, Palanicawandar, Renuka, Lim, Michael, Gallipoli, Paolo, Dennis, Mike, Campbell, Victoria Louise, Dillon, Richard, Collins, Angela, Whitmill, Richard, Loizou, Eleana   +52 more
core   +1 more source

Extranodal Organ Involvement in Chronic Lymphocytic Leukemia: Clinical Features and Outcomes With Bruton Tyrosine Kinase and BCL-2 Inhibitors. [PDF]

Cancer Med
ABSTRACT Background Although chronic lymphocytic leukemia (CLL) typically follows an indolent course involving blood, lymph nodes, and bone marrow, extranodal organ involvement is rare and poorly characterized. Methods We retrospectively analyzed 19 patients with histologically confirmed extranodal CLL or small lymphocytic lymphoma (SLL), assessing ...
Schulze FJ, Shumilov E, Behringer A, Kerkhoff A, Eckhardt M, Bätker S, Maulhardt M, Lenz G, Pohlmann A.   +8 more
europepmc   +2 more sources

Venetoclax causes metabolic reprogramming independent of BCL-2 inhibition [PDF]

, 2020
BH3-mimetics are a new class of anti-cancer drugs that inhibit anti-apoptotic Bcl-2 proteins. In doing so, BH3-mimetics sensitise to cell death.
O'Neill, Katelyn, Luo, Xu, Sumpton, David, Cloix, Catherine, Roca Portoles, Alba, Tait, Stephen W.G., Blanco, Giovanny, Mullin, Margaret, Mackay, Gillian M., Lemgruber Soares, Leandro   +9 more
core   +1 more source

Venetoclax plus LDAC for patients with untreated AML ineligible for intensive chemotherapy: phase 3 randomized placebo-controlled trial.

, 2020
BACKGROUND Effective treatment options are limited for patients with acute myeloid leukemia (AML) who cannot tolerate intensive chemotherapy. METHODS Adults ≥18 years with newly diagnosed AML ineligible for intensive chemotherapy were enrolled ...
Novak, Jan, Laribi, Kamel, Kim, Inho, Samoilova, Olga, Gopalakrishnan, Sathej, Panayiotidis, Panayiotis, Stevens, Don, Anagnostopoulos, Achilles, Hayslip, John, Hou, Jing-Zhou, Bergeron, Julie, Jiang, Qi, McDonald, Andrew Bruce, Ivanov, Vladimir, Pagoni, Maria, Mendes, Wellington L, Chyla, Brenda, Murthy, Vidhya, Montesinos, Pau, DiNardo, Courtney D, Wei, Andrew Henry, Fiedler, Walter, Hu, Yu, Yamauchi, Takahiro   +23 more
core   +1 more source

Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies

Cancer Cell International, 2020
Venetoclax has been approved by the United States Food and Drug Administration since 2016 as a monotherapy for treating patients with relapsed/refractory chronic lymphocytic leukemia having 17p deletion.
XiaoYan Yue, Qingxiao Chen, JingSong He
doaj   +1 more source

Venetoclax-containing regimens in acute myeloid leukemia

Therapeutic Advances in Hematology, 2021
Venetoclax in combination with hypomethylating agents (HMAs) or low-dose cytarabine (LDAC) has demonstrated exceptional activity in elderly and unfit patients with newly diagnosed acute myeloid leukemia (AML).
Ibrahim Aldoss, Vinod Pullarkat, Anthony S. Stein   +2 more
doaj   +1 more source

MIMA study - Venetoclax

, 2022
   images of multiplex IHC staining of MMTV-PyMT mammary carcinoma tissue three days after local Venetoclax drug ...
Zuzana Tatarova (12507553)
core   +1 more source

Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia

Journal of Hematology & Oncology, 2022
Inhibitors of B cell receptor (BCR) signaling such as the Bruton’s tyrosine kinase (BTK) inhibitors are effective therapeutics for chronic lymphocytic leukemia (CLL).
Elizabeth M. Muhowski, Janani Ravikrishnan, Britten Gordon, Lianbo Yu, Shrilekha Misra, Brandi Walker, Sudharshan Eathiraj, Deepa Sampath, Kerry A. Rogers, John C. Byrd, Jennifer A. Woyach   +10 more
doaj   +1 more source

Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa/Bim/Mcl-1/p-Chk1 axis

Cell Death and Disease, 2022
Venetoclax plus cytarabine therapy is approved for elderly acute myeloid leukemia (AML) patients and needs further improvement. We studied the mechanisms of venetoclax plus cytarabine treatment and searched for a third agent to enhance their effects ...
Jingyi Zhang, Yuetong Wang, Chujie Yin, Ping Gong, Zhenwei Zhang, Linxiang Zhao, Samuel Waxman, Yongkui Jing   +7 more
doaj   +1 more source

Electron transport chain and mTOR inhibition synergistically decrease CD40 signaling and counteract venetoclax resistance in chronic lymphocytic leukemia

Haematologica, 2023
CD40 signaling upregulates BCL-XL and MCL-1 expression in the chronic lymphocytic leukemia (CLL) lymph node microenvironment, affording resistance to the BCL-2 inhibitor, venetoclax.
Zhenghao Chen, Gaspard Cretenet, Valeria Carnazzo, Helga Simon-Molas, Arnon P. Kater, Gerritje J. W. van der Windt, Eric Eldering   +6 more
doaj   +1 more source